These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8038457)

  • 1. Immunological responses critical to the therapeutic effects of adriamycin plus interleukin 2 in C57BL/6 mice bearing syngeneic EL4 lymphoma.
    Ho RL; Maccubbin DL; Ujházy P; Zaleskis G; Eppolito C; Mihich E; Ehrke MJ
    Oncol Res; 1993; 5(9):363-72. PubMed ID: 8038457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a safe and effective adriamycin plus interleukin 2 therapy against both adriamycin-sensitive and -resistant lymphomas.
    Ho RL; Maccubbin D; Zaleskis G; Krawczyk C; Wing K; Mihich E; Ehrke MJ
    Oncol Res; 1993; 5(9):373-81. PubMed ID: 8038458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modification of host antitumor defense mechanisms in mice by progressively growing tumor.
    Maccubbin DL; Mace KF; Ehrke MJ; Mihich E
    Cancer Res; 1989 Aug; 49(15):4216-24. PubMed ID: 2525950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracellular doxorubicin kinetics in lymphoma cells and lymphocytes infiltrating the tumor area in vivo: a flow cytometric study.
    Zaleskis G; Ho RL; Diegelman P; Maccubbin D; Ujházy P; Mihich E; Ehrke MJ
    Oncol Res; 1994; 6(4-5):183-94. PubMed ID: 7841541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor protection from the murine T-cell leukemia/lymphoma EL4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor and interleukin-2.
    Vallera DA; Taylor PA; Aukerman SL; Blazar BR
    Cancer Res; 1993 Sep; 53(18):4273-80. PubMed ID: 8364923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells.
    Schultz KR; Klarnet JP; Peace DJ; Cheever MA; Badger CC; Bernstein ID; Greenberg PD
    Cancer Res; 1990 Sep; 50(17):5421-5. PubMed ID: 2386946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice.
    Ewens A; Luo L; Berleth E; Alderfer J; Wollman R; Hafeez BB; Kanter P; Mihich E; Ehrke MJ
    Cancer Res; 2006 May; 66(10):5419-26. PubMed ID: 16707470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matching of chemotherapy to mouse strain and lymphoid tumor type to prevent tumor-induced suppression of specific T- and B-cell functions.
    Faanes RB; Merluzzi VJ; Williams N; Tarnowski GS; Ralph P
    Cancer Res; 1979 Nov; 39(11):4564-74. PubMed ID: 315269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.
    Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T
    Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adriamycin-induced modulation of host defenses in tumor-bearing mice.
    Maccubbin DL; Wing KR; Mace KF; Ho RL; Ehrke MJ; Mihich E
    Cancer Res; 1992 Jul; 52(13):3572-6. PubMed ID: 1617626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
    Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of nonspecific killer cells by interleukin 2-containing supernatants.
    Teh HS; Yu M
    J Immunol; 1983 Oct; 131(4):1827-33. PubMed ID: 6194216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effect of NK1.1(+) T cells as well as NK cells against intraperitoneal tumors in mice.
    Kawamura T; Seki S; Takeda K; Narita J; Ebe Y; Naito M; Hiraide H; Abo T
    Cell Immunol; 1999 May; 193(2):219-25. PubMed ID: 10222065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells.
    Li T; Harada M; Tamada K; Abe K; Nomoto K
    Anticancer Res; 1997; 17(6D):4259-68. PubMed ID: 9494518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study of the immunological mechanism of anti-tumor effects of 5-FU by establishing EL4 tumor-bearing mouse models].
    Li ML; Li CG; Shu XH; Li MX; Jia YJ; Qin ZH
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Nov; 23(11):1010-3. PubMed ID: 17988579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoreactive and heat shock protein 60-recognizing CD4+ T-cells show antitumor activity against syngeneic fibrosarcoma.
    Harada M; Matsuzaki G; Yoshikai Y; Kobayashi N; Kurosawa S; Takimoto H; Nomoto K
    Cancer Res; 1993 Jan; 53(1):106-11. PubMed ID: 8093229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Establishment of EL4 tumor-bearing mouse models and investigation on immunological mechanisms of anti-tumor effect of melphalan].
    Li ML; Li CG; Shu XH; Jia YJ; Qin ZH
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Mar; 22(2):235-8. PubMed ID: 16507262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction and persistence in vivo of NK/LAK activity by a mannoprotein component of Candida albicans cell wall.
    Scaringi L; Cornacchione P; Rosati E; Fettucciari K; Rossi R; Marconi P
    Cell Immunol; 1994 May; 155(2):265-82. PubMed ID: 8181065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma.
    Micallef MJ; Tanimoto T; Kohno K; Ikeda M; Kurimoto M
    Cancer Res; 1997 Oct; 57(20):4557-63. PubMed ID: 9377569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Induction of LAK cells in peritoneal cavity of mice after ip injection of OK-432 and antitumor effect of these LAK cells].
    Ishida N; Saito M; Nanjo M
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2681-90. PubMed ID: 6508321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.